Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 14, 2022 5:45pm
165 Views
Post# 34895422

RE:Last target was around 7,50$,

RE:Last target was around 7,50$,
sylvain_007 wrote: People spoke about 10$ if GUD return on the finance market. Short term, probably 7$ is possible.


There is a sense of pride with going to market at INCREASED valuations.  They want to be able to say that ... if at all possible.

Therefore, I would not look at $10 as an entry point for issuing more shares ... will be higher IMO.

Then again ... can't say for certain as time sensitive opportunities could arise.  In such a case, look for cash and debt to be used prior to going to market (if at all possible).

Regardless - they know how to build a drug licensing/marketing firm.  Slow and steady wins this race.
<< Previous
Bullboard Posts
Next >>